Back to search

Michigan State University

PRECLINICAL DEVELOPMENT OF ALPHA-PARTICLE THERAPEUTICS

Abstract

dc:description

Internal radiation therapy is an alternative method to external beam radiation therapy for the treatment of cancer. Alpha (α)-particle based internal radiation therapy methods are being explored to improve the efficacy and toxicity compared to using beta (β-)-emitting isotopes. Two α-particle delivery platforms were developed; Pb-212-GlaS-Fc, which utilizes a systemic targeted approach, and Bi-212-MAA, which is a short-lived locoregionally delivered embolic radiopharmaceutical. Both of these radiopharmaceuticals were shown to be efficacious in treatment of cancer cells and be potential clinic therapeutics. Further, Bi-212-MAA was used as a platform to understand cellular and molecular responses of cancer to α-particle radiation. It was found that cancer cells are unable to utilize certain canonical radiation resistant responses, such as cell cycle control, when treated with α-particles. Additionally, cytokine production was dysregulated in these cells after treatment. These findings indicate that these two new delivery strategies have potential for translation to the clinic and that Bi-212-MAA can be used as a tool to elucidate additional molecular effects of α-particles on cancer cells.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kauffman, Nathan
Contributors dc:contributor
  • Zinn, Kurt R.
  • Neubig, Richard
  • Alessio, Adam
  • Magestro, Leanne

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • Attribution 4.0 International
Language dc:language
English

Identifiers

dc:identifier.*
Identifier
etd:50984
local:Kauffman_grad.msu_0128D_20019

Chain of custody

source
Harvested from
Michigan State University
Base URL
d.lib.msu.edu/oai
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kauffman, Nathan. PRECLINICAL DEVELOPMENT OF ALPHA-PARTICLE THERAPEUTICS. 2023. https://doi.org/doi:10.25335/wdn0-tt47